VolitionRx Limited Announces Pricing of $16.5 Million Underwritten Public Offering of Common StockPRNewsWire • 06/01/23
VolitionRx Limited Announces Proposed Underwritten Public Offering of Common StockPRNewsWire • 05/31/23
Volition Study shows Nucleosome Concentrations are a useful tool for Canine Cancer Treatment MonitoringPRNewsWire • 05/11/23
VolitionRx Limited Announces First Quarter 2023 Financial Results and Business UpdatePRNewsWire • 05/10/23
VolitionRx Limited Schedules First Quarter 2023 Earnings Conference Call and Business UpdatePRNewsWire • 05/05/23
VolitionRx posts 240% rise in 2022 revenue; outlines upcoming milestonesProactive Investors • 03/16/23
VolitionRx Limited Announces Full Fiscal Year 2022 Financial Results and Business UpdatePRNewsWire • 03/15/23
VolitionRx Limited Schedules Full Year 2022 Earnings Conference Call and Business UpdatePRNewsWire • 03/10/23
VolitionRx Limited Announces Closing of $8.7 Million Underwritten Public Offering of Common StockPRNewsWire • 02/22/23
VolitionRx Limited Announces Pricing of $7.525 Million Underwritten Public Offering of Common StockPRNewsWire • 02/17/23
VolitionRx says Nu.Q Vet Cancer Test now available for pre-order at the point-of-care through Heska CorporationProactive Investors • 02/16/23
Volition's Nu.Q® Vet Cancer Test Now Available for Pre-Order at The Point-of-Care Through Heska CorporationPRNewsWire • 02/16/23
VolitionRx announces expansion of availability of Nu.Q Vet Cancer Test availability through IDEXX's reference laboratory networkProactive Investors • 01/12/23
Volition Announces Expansion of Availability of the Nu.Q® Vet Cancer Test Through IDEXX's Reference Laboratory NetworkPRNewsWire • 01/12/23
VolitionRx highlights 2022 achievements as it advances to commercial operationsProactive Investors • 01/09/23